STMN2 and amyotrophic lateral sclerosis: As a critical neuronal maintenance factor (Shin et al., 2014; Klim et al., 2019), attenuating STMN2 expression may be a viable therapeutic approach to modify disease in a large proportion of both fALS and sALS patients, and reinforces its potential development for use as a prognostic marker or in clinical trials for ALS (Klim et al., 2019; Melamed et al., 2019) and other neurodegenerative diseases (Wang et al., 2019; Prudencio et al., 2020).